Odronextamab
(Anti-human CD20 CD3 bispecific mAb, human IgG4-Kappa; REGN19179)
Catalog No.: PC-Ab1035Not For Human Use, Lab Use Only.
Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based CD3 x CD20 bispecific antibody (bsAb), binds to CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity independent of T-cell receptor recognition. Odronextamab has demonstrated preliminary efficacy in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)..
Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based CD3 x CD20 bispecific antibody (bsAb), binds to CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity independent of T-cell receptor recognition. Odronextamab has demonstrated preliminary efficacy in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Physicochemical Properties
M.Wt
Formula
Human IgG4-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
